Clarivate (CLVT) Q2 2025 Earnings Transcript

Clarivate reported Q2 revenue of $621 million and first-half revenue of $1.2 billion, with organic ACV up 1.3% and recurring organic revenue growing nearly 1% in the quarter. Adjusted EBITDA margin improved 50 bps to 41% in the first half, free cash flow reached $161 million, and management reaffirmed 2025 guidance, including organic ACV growth of about 1.5%, adjusted EBITDA margin near 41%, and free cash flow of about $340 million. Offsetting the operating progress, revenue was held down by divestitures/disposals, net loss was $72 million, and management flagged ongoing headwinds from inflation, incentive comp, and asset sales.

Analysis

CLVT is starting to look less like a broken growth story and more like a slow re-rating candidate if the market believes recurring mix and renewal quality can keep compounding while the portfolio gets simplified. The key second-order effect is that divestitures are not just shrinking revenue; they are also removing lower-quality volatility, which should mechanically improve multiple perception if management can prove that the remaining book can hold low-single-digit organic growth through FY26. That matters because a business with 80%+ recurring mix, high renewal rates, and modest growth typically trades more like an information-services annuity than a restructuring story.

The bigger underwriting issue is that the easy margin expansion is likely behind them. Cost actions are supporting EBITDA now, but inflation and incentive comp create a ceiling on further margin gains, while the refinancing decision trades near-term interest expense for maturity certainty and FX/rate flexibility. In other words, CLVT is choosing survivability and capital allocation optionality over immediate EPS optimization, which is rational but also means equity upside depends on execution in the core segments, not financial engineering.

The market may also be underestimating the lag structure of the IP AI tailwind. More filings today do not translate to annuity monetization for a few years, so the near-term upside is mostly narrative unless patent activity stays broad-based outside China. Conversely, the A&G business looks more defensible than the headline macro warnings imply because the product mix shift toward subscriptions should reduce budget cyclicality; if renewal quality holds into 2026, the bearish thesis built around federal and university pressure may prove too linear.

The contrarian risk is that the strategic review creates a waiting game without a catalyst. If promised disposals slip again, the market may conclude that management is struggling to execute portfolio optimization, which would cap any multiple expansion even if fundamentals improve modestly. This makes the next 6 months more about evidence of renewal durability and disposal closure than about absolute growth rates.

Key Decisions for Investors

• Long CLVT on a 3-6 month horizon via common equity only on pullbacks; thesis is that recurring-mix improvement and renewal stability can support a valuation re-rate before the strategic review conclusion in Feb-2026. Risk/reward is attractive if the stock still prices this as a distressed restructure rather than a higher-quality subscription data asset.
• Use a call spread in CLVT into year-end 2025 (e.g., 6-9 month upside exposure) to express upside from strategic-review optionality while limiting downside if disposal timing slips again. Best entry is after any post-earnings digestion or headline-driven weakness.
• Pair long CLVT / short a more cyclically exposed research-and-data peer basket to isolate the recurring-revenue mix story. The trade works if investors start paying for subscription durability rather than top-line growth purity.
• Avoid chasing the IP AI narrative in the near term; it is better viewed as a 12-24 month earnings lever than a next-quarter catalyst. If you want exposure, structure it as a longer-dated bullish position rather than a momentum trade.
• Set a tactical stop if management revises FY26 transition timing again or if renewal commentary in A&G deteriorates; that would signal the core thesis is being deferred rather than validated.